Jun 30, 2009Genmab’s Total Number of Voting Rights and Total Share Capital
Jun 17, 2009Grant of Warrants to Board Members, Management and Employees in Genmab A/S
Jun 16, 2009FDA Extends Review of ARZERRA (Ofatumumab)
Jun 10, 2009Capital Increase in Genmab as a Result of Employee Warrant Exercise
Jun 10, 2009Recruitment Completed in Zalutumumab Head and Neck Cancer Pivotal Study
Jun 3, 2009Genmab Announces Partial Clinical Hold on Zalutumumab Studies
Jun 3, 2009Genmab to Present at Three June Investor Conferences
May 29, 2009FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab’s Arzerra(TM) (Ofatumumab)
May 12, 2009Genmab Announces 2009 First Quarter Results
May 11, 2009Ofatumumab and R1507 Data to be Presented at ASCO
May 11, 2009Genmab to Attend Merrill Lynch Conference
May 4, 2009FDA Advisory Committee to Review Arzerra™ (Ofatumumab)
Apr 15, 2009Constitution of the Board of Directors in Genmab and Grant of Warrants to Employees
Apr 15, 2009Passing of Genmab A/S’ Annual General Meeting
Apr 3, 2009Arzerra™ (ofatumumab) Granted Priority Review by FDA
Mar 31, 2009Genmab’s Total Number of Voting Rights and Total Share Capital
Mar 25, 2009Genmab A/S Summons Annual General Meeting
Mar 23, 2009Genmab to Attend Kempen & Co Life Sciences Conference 2009
Mar 4, 2009Capital Increase in Genmab as a Result of Employee Warrant Exercise
Feb 26, 2009Arzerra™ (ofatumumab) MAA Accepted by EMEA
Feb 26, 2009Genmab to Attend Two March Investor Conferences
Feb 24, 2009Genmab Announces Year End 2008 Financial Results
Feb 5, 2009GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Feb 5, 2009Major Shareholder Announcement
Jan 30, 2009GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
Jan 8, 2009Genmab to Present at 27th Annual JPMorgan Healthcare Conference
Jan 5, 2009Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer